HER2-Positive Breast Cancer. (2018)

• Record Type: Book
• Further Information: Note: Sara Hurvitz, Kelly McCann.
• Authors: Hurvitz, Sara; McCann, Kelly
• Contents: Background/testing 1. The HER2 alteration in breast cancer 2. HER2 testing in the era of changing guidelines Advanced Disease 3. Optimal first-line treatment of HER2+ advanced disease 4. Second line therapy and beyond 5. HER2+ CNS metastases Therapeutics 6. Neoadjuvant therapy 7. Adjuvant therapy 8. Outcomes based on HR status in early stage disease 9. De-escalation of therapy for small tumor Toxicity considerations 10. Cardiac toxicity of HER2-targeted regimens 11. Non-cardiac toxicity of HER2-targeted therapy Therapies on the horizon 12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc) 13. Harnessing the immune system in HER2+ disease 14. Biosimilars
• Publisher Details: Elsevier
• Publication Date: 2018
• Extent: 1 online resource (264 pages)
• Languages: English
• ISBNs: 9780323581233; 0323581234
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.